This phase III trial is comparing how well combination chemotherapy works, when given with bortezomib (another chemotherapy drug), for the treatment of newly diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) and T-Cell Lymphoblastic Lymphoma.
This trial is treating patients with Acute Lymphoblastic Leukaemia, Acute Lymphoblastic Lymphoma.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
- NCI-2014-00712, NCI-2014-00712, AALL1231, U10CA180886, U10CA098543
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
Other Non-Commercial Sponsor
National Cancer Institute (NCI)
This randomized phase III trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma. Bortezomib may help reduce the number of leukemia or lymphoma cells by blocking some of the enzymes needed for cell growth. It may also help chemotherapy work better by making cancer cells more sensitive to the drugs. It is not yet known if giving standard chemotherapy with or without bortezomib is more effective in treating T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
Recruiting Hospitals Read More